AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38091416 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared group (indocyanine green)
Number of subjects: 108
Study 38091416 — intervention group
Group type: COMPARATOR
Intervention: Non-near-infrared group
Number of subjects: 108
Study 38091501 — intervention group
Group type: EXPERIMENTAL
Intervention: ANB at the onset
Number of subjects: 80
Study 38091501 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 38091531 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose recombinant influenza vaccine (Flublok Quadrivalent)
Number of subjects: 1630328
Study 38091531 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose influenza vaccines
Number of subjects: 1630328
Study 38091530 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1345 (50 μg)
Number of subjects: 35541
Study 38091530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35541
Study 38091578 — intervention group
Group type: EXPERIMENTAL
Intervention: T-reg graft alone
Number of subjects: 24
Study 38091578 — intervention group
Group type: COMPARATOR
Intervention: T-reg graft plus tacrolimus
Number of subjects: 24
Study 38091943 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal total mesorectal resection (taTME)
Number of subjects: 2502
Study 38091943 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic total mesorectal excision (laTME)
Number of subjects: 2502
Study 38092009 — intervention group
Group type: EXPERIMENTAL
Intervention: Golidocitinib 150 mg once daily until disease progression or other discontinuation criteria were met.
Number of subjects: 88
Study 38092009 — intervention group
Group type: EXPERIMENTAL
Intervention: Golidocitinib 150 mg once daily
Number of subjects: 88
Study 38092151 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic Acid (FA) supplementation at 800 μg/day for 12 weeks
Number of subjects: 60
Study 38092151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 38092153 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg oral daily)
Number of subjects: 50
Study 38092153 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 50
Study 38092225 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 100/200 mg by bodyweight every 2 weeks for 52 weeks
Number of subjects: 175
Study 38092225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 38092228 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) for four cycles
Number of subjects: 50
Study 38092272 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice nitrate-rich (BRJ-NO3), 800 mg of NO
Number of subjects: 14
Study 38092272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 38092285 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making
Number of subjects: 0
Study 38092285 — intervention group
Group type: COMPARATOR
Intervention: Motivational interviewing plus cognitive behavioral therapy
Number of subjects: 0
Study 38092790 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazdutide (up to 6 mg)
Number of subjects: 0
Study 38092790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38092805 — intervention group
Group type: EXPERIMENTAL
Intervention: Coherent breathing at ~5.5 breaths/min for ~10 min/day over 4 weeks
Number of subjects: 400
Study 38092805 — intervention group
Group type: COMPARATOR
Intervention: Matched attention-placebo at 12 breaths/min for ~10 min/day over 4 weeks
Number of subjects: 400
Study 38092871 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum choline levels (highest levels Q4)
Number of subjects: 199
Study 38092871 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated choline levels (per SD, 11.49 μg/mL)
Number of subjects: 199
Study 38092871 — intervention group
Group type: COMPARATOR
Intervention: Lowest choline levels (Q1 group)
Number of subjects: 199
Study 38092897 — intervention group
Group type: EXPERIMENTAL
Intervention: AP30663, an inhibitor of the K channel
Number of subjects: 0
Study 38093118 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative cardiopulmonary exercise test (CPET) variables, specifically the slope of the relation between minute ventilation and carbon dioxide production (VE/VCO2)
Number of subjects: 102
Study 38093118 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis adjusted for surgical approach (open vs minimally invasive)
Number of subjects: 102
Study 38093181 — intervention group
Group type: EXPERIMENTAL
Intervention: Low eosinophil count <0.01 G/L
Number of subjects: 156
Study 38093181 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophil count 0-0.07 G/L
Number of subjects: 156
Study 38093181 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophil count 0.07-0.172 G/L
Number of subjects: 156
Study 38093181 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophil count <0.01 G/L
Number of subjects: 156
Study 38093181 — intervention group
Group type: EXPERIMENTAL
Intervention: CIBLE score
Number of subjects: 156
Study 38093374 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-weight support (BWS) gait training
Number of subjects: 33
Study 38093381 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry suction technique
Number of subjects: 200
Study 38093381 — intervention group
Group type: COMPARATOR
Intervention: Wet suction technique
Number of subjects: 200
Study 38093394 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional training with elastic band
Number of subjects: 41
Study 38093394 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise (machine resistance)
Number of subjects: 41
Study 38093439 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (Hgb threshold 7.0 g/dL)
Number of subjects: 65
Study 38093439 — intervention group
Group type: COMPARATOR
Intervention: Conservative transfusion strategy (Hgb threshold 5.5 g/dL)
Number of subjects: 65
Study 38093467 — intervention group
Group type: EXPERIMENTAL
Intervention: High Empowerment
Number of subjects: 633
Study 38093467 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately High Empowerment
Number of subjects: 633
Study 38093467 — intervention group
Group type: EXPERIMENTAL
Intervention: Normative
Number of subjects: 633
Study 38093467 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Empowerment
Number of subjects: 633
Study 38093467 — intervention group
Group type: EXPERIMENTAL
Intervention: High Information
Number of subjects: 633
Study 38093803 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-delivered cognitive behavioural therapy (iCBT) program for 9 weeks
Number of subjects: 0
Study 38093803 — intervention group
Group type: COMPARATOR
Intervention: Online Depression Feedback (ODF) group
Number of subjects: 0
Study 38093803 — intervention group
Group type: COMPARATOR
Intervention: Both iCBT and ODF
Number of subjects: 0
Study 38093803 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT
Number of subjects: 0
Study 38093975 — intervention group
Group type: EXPERIMENTAL
Intervention: Rutan
Number of subjects: 0
Study 38093975 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38094620 — intervention group
Group type: EXPERIMENTAL
Intervention: FFT-MCC (Family-focused therapy with MyCoachConnect app)
Number of subjects: 65
Study 38094620 — intervention group
Group type: COMPARATOR
Intervention: FFT-Track (Family-focused therapy with mood tracking only)
Number of subjects: 65
Study 38094629 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields (TTFields) therapy
Number of subjects: 0
Study 38094629 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields (TTFields)
Number of subjects: 0
Study 38094931 — intervention group
Group type: EXPERIMENTAL
Intervention: Lessons in Affect Regulation to Keep Stress and Pain UndeR control (LARKSPUR)
Number of subjects: 95
Study 38094931 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 95
Study 38094933 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Identification and Communication Toolkit (PICT)
Number of subjects: 100
Study 38095056 — intervention group
Group type: EXPERIMENTAL
Intervention: HER3-DXd (patritumab deruxtecan)
Number of subjects: 0
Study 38095056 — intervention group
Group type: COMPARATOR
Intervention: Platinum-based chemotherapy
Number of subjects: 0
Study 38095330 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-stroke aphasia
Number of subjects: 23
Study 38095452 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 99
Study 38095452 — intervention group
Group type: EXPERIMENTAL
Intervention: PSQI and ASPI
Number of subjects: 99
Study 38095452 — intervention group
Group type: EXPERIMENTAL
Intervention: PSQI and BASFI
Number of subjects: 99
Study 38095657 — intervention group
Group type: EXPERIMENTAL
Intervention: Survodutide (dose-response effects)
Number of subjects: 413
Study 38095657 — intervention group
Group type: COMPARATOR
Intervention: Semaglutide
Number of subjects: 413
Study 38095657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study 38095673 — intervention group
Group type: EXPERIMENTAL
Intervention: Photon RT
Number of subjects: 35
Study 38095673 — intervention group
Group type: COMPARATOR
Intervention: Proton RT
Number of subjects: 35
Study 38095675 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (ABA)
Number of subjects: 0
Study 38095675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38095692 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (90 mg every 8 or 12 weeks)
Number of subjects: 348
Study 38095714 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound-guided fluid resuscitation (LUGFR)
Number of subjects: 72
Study 38095714 — intervention group
Group type: COMPARATOR
Intervention: Usual fluid resuscitation (Control)
Number of subjects: 72
Study 38095713 — intervention group
Group type: EXPERIMENTAL
Intervention: Munich Berlin Symptom Questionnaires (MBSQs) and supplementary scoring sheets (SSSs)
Number of subjects: 10
Study 38095797 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional intervention (patient education, physical exercise, CBT-based group program, nutritional counselling)
Number of subjects: 7
Study 38095797 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional intervention
Number of subjects: 7
Study 38095800 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care
Number of subjects: 30
Study 38095800 — intervention group
Group type: EXPERIMENTAL
Intervention: oXiris
Number of subjects: 30
Study 38095800 — intervention group
Group type: EXPERIMENTAL
Intervention: Toraymyxin
Number of subjects: 30
Study 38095878 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and atezolizumab (1200 mg every 3 weeks)
Number of subjects: 106
Study 38095878 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin alone
Number of subjects: 106
Study 38095881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy with bevacizumab
Number of subjects: 617
Study 38095881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy without bevacizumab
Number of subjects: 617
Study 38095881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy with carboplatin
Number of subjects: 617
Study 38095881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy with cisplatin
Number of subjects: 617
Study 38095881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy with prior CRT
Number of subjects: 617
Study 38095881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy without prior CRT
Number of subjects: 617
Study 38095881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy in squamous type
Number of subjects: 617
Study 38095881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy in nonsquamous type
Number of subjects: 617
Study 38095881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy with bevacizumab (intention-to-treat)
Number of subjects: 617
Study 38095881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy without bevacizumab (intention-to-treat)
Number of subjects: 617
Study 38095881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy with carboplatin (intention-to-treat)
Number of subjects: 617
Study 38095881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy with cisplatin (intention-to-treat)
Number of subjects: 617
Study 38095881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy with prior CRT (intention-to-treat)
Number of subjects: 617
Study 38095881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy without prior CRT (intention-to-treat)
Number of subjects: 617
Study 38095881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy in squamous type (intention-to-treat)
Number of subjects: 617
Study 38095881 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy in nonsquamous type (intention-to-treat)
Number of subjects: 617
Study 38095903 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary snoring (AHI <1)
Number of subjects: 459
Study 38095903 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild obstructive sleep apnea (AHI 1-3)
Number of subjects: 459
Study 38095903 — intervention group
Group type: COMPARATOR
Intervention: Demographic and clinical characteristics
Number of subjects: 459
Study 38095903 — intervention group
Group type: COMPARATOR
Intervention: Weighted combination of clinical predictors
Number of subjects: 459
Study 38095899 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based checklist administered every 6 hours from enrollment to organ retrieval.
Number of subjects: 1535
Study 38095899 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to the checklist higher than 79.0%.
Number of subjects: 1535
Study 38095899 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided to control group.
Number of subjects: 1535
Study 38095939 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher morning positive affect
Number of subjects: 0
Study 38095939 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher morning negative affect
Number of subjects: 0
Study 38095939 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher characteristic morning positive affect
Number of subjects: 0
Study 38095939 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher characteristic morning negative affect
Number of subjects: 0
Study 38096002 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support system (DSS) and machine learning web application for 3 months (experimental group)
Number of subjects: 100
Study 38096002 — intervention group
Group type: COMPARATOR
Intervention: Not exposed to the DSS and machine learning web application (control group)
Number of subjects: 100
Study 38096002 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly medication diary and standardized self-reports (both groups)
Number of subjects: 100
Study 38096017 — intervention group
Group type: EXPERIMENTAL
Intervention: MedAdhere app
Number of subjects: 105
Study 38096017 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study 38096020 — intervention group
Group type: EXPERIMENTAL
Intervention: Afini intervention group (1175 caregiver-child dyads)
Number of subjects: 2471
Study 38096020 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit intervention group (316 caregiver-child dyads)
Number of subjects: 2471
Study 38096020 — intervention group
Group type: COMPARATOR
Intervention: Control group (980 caregiver-child dyads)
Number of subjects: 2471
Study 38096020 — intervention group
Group type: EXPERIMENTAL
Intervention: Afini intervention group
Number of subjects: 2471
Study 38096020 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit intervention group
Number of subjects: 2471
Study 38096020 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2471
Study 38096102 — intervention group
Group type: EXPERIMENTAL
Intervention: MKI therapy (cohort 1)
Number of subjects: 647
Study 38096102 — intervention group
Group type: COMPARATOR
Intervention: Active surveillance (cohort 2)
Number of subjects: 647
Study 38096102 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance transitioning to MKI therapy (cohort 2)
Number of subjects: 647
Study 38096105 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive systemic corticosteroids
Number of subjects: 0
Study 38096106 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0
Study 38096106 — intervention group
Group type: COMPARATOR
Intervention: GLP1-mediated weight loss
Number of subjects: 0
Study 38096190 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study 38096190 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 38096190 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab
Number of subjects: 0
Study 38096261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice or cranberry products
Number of subjects: 0
Study 38096261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38096402 — intervention group
Group type: EXPERIMENTAL
Intervention: Ontamalimab 25 mg induction therapy
Number of subjects: 1025
Study 38096402 — intervention group
Group type: EXPERIMENTAL
Intervention: Ontamalimab 75 mg induction therapy
Number of subjects: 1025
Study 38096402 — intervention group
Group type: EXPERIMENTAL
Intervention: Ontamalimab 25 mg maintenance therapy
Number of subjects: 1025
Study 38096402 — intervention group
Group type: EXPERIMENTAL
Intervention: Ontamalimab 75 mg maintenance therapy
Number of subjects: 1025
Study 38096402 — intervention group
Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 1025
Study 38096461 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (G) plus chemotherapy (bendamustine, CHOP, or CVP)
Number of subjects: 0
Study 38096461 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (R) plus chemotherapy (bendamustine, CHOP, or CVP)
Number of subjects: 0
Study 38096462 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-L-Asparaginase (PEG-ASNASE, 2,500 IU/sqm once a week × 4)
Number of subjects: 1097
Study 38096472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobimetinib plus vemurafenib
Number of subjects: 31
Study 38096472 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 31
Study 38096705 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin ± amoxicillin
Number of subjects: 652
Study 38096705 — intervention group
Group type: EXPERIMENTAL
Intervention: None/primary education (vs university)
Number of subjects: 652
Study 38096705 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean birth
Number of subjects: 652
Study 38096705 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic receipt per physician discretion (vs for cesarean prophylaxis)
Number of subjects: 652
Study 38096705 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 factor model (cesarean birth, receipt of antibiotics per physician discretion, university education)
Number of subjects: 652
Study 38096764 — intervention group
Group type: EXPERIMENTAL
Intervention: Neovaginal reconstruction
Number of subjects: 334
Study 38096764 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap reconstruction
Number of subjects: 334
Study 38096764 — intervention group
Group type: COMPARATOR
Intervention: No reconstruction
Number of subjects: 334
Study 38096946 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing patient-specific out-of-pocket cost estimates during clinical encounters.
Number of subjects: 0
Study 38096946 — intervention group
Group type: COMPARATOR
Intervention: Control group without access to patient-specific out-of-pocket cost estimates.
Number of subjects: 0
Study 38097379 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex molecular testing
Number of subjects: 1157
Study 38097379 — intervention group
Group type: COMPARATOR
Intervention: Pre-intervention testing
Number of subjects: 1157
Study 38097379 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention testing
Number of subjects: 1157
Study 38097552 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC01 (broadly neutralizing monoclonal antibody)
Number of subjects: 0
Study 38097605 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib plus docetaxel
Number of subjects: 0
Study 38097741 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (O) maintenance therapy
Number of subjects: 182
Study 38097741 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 182
Study 38097741 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (O)
Number of subjects: 182
Study 38097862 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 4304
Study 38097862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4304
Study 38097898 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactation management model
Number of subjects: 0
Study 38097898 — intervention group
Group type: COMPARATOR
Intervention: Routine lactation practices in clinic (Control)
Number of subjects: 0
Study 38097899 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal Massage and Warm Compresses (PeMWaC)
Number of subjects: 496
Study 38097899 — intervention group
Group type: COMPARATOR
Intervention: Control group (hands-on)
Number of subjects: 496
Study 38097933 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable device intervention with behavioral change techniques (BCTs) for physical activity promotion
Number of subjects: 40
Study 38097933 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract)
Number of subjects: 40
Study 38097963 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD) with 6% low-protein formula (6% LPF) and dietary counseling
Number of subjects: 66
Study 38097963 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet (LPD) counseling alone
Number of subjects: 66
Study 38098022 — intervention group
Group type: EXPERIMENTAL
Intervention: S. persica chewing stick (MCS)
Number of subjects: 78